ThaiPR.NET https://www.thaipr.net/location/bagsvaerd-denmark Press Release Distribution Center of Thailand Thu, 23 Apr 2026 17:31:43 +0700 hourly 1 https://wordpress.org/?v=6.1.1 <![CDATA[Wegovy™ Demonstrated Significant and Sustained Weight Loss in Two-Year Study in Adults With Obesity]]> https://www.thaipr.net/en/health_en/3118556 Mon, 08 Nov 2021 08:10:00 +0700 health_en https://www.thaipr.net/en/health_en/3118556 The STEP 5 trial demonstrated an average weight loss of 15.2% with Wegovy™ at 104-weeks when used with a reduced calorie meal plan and increased physical activity vs. 2.6% with placebo The trial also showed that 77.1% of study participants who received Wegovy™ lost at least 5% of their body weight, compared to 34.4% of […]

The post Wegovy™ Demonstrated Significant and Sustained Weight Loss in Two-Year Study in Adults With Obesity appeared first on ThaiPR.NET.

]]> <![CDATA[Semaglutide in people with obesity: boosts wellbeing and ability to perform daily physical activities]]> https://www.thaipr.net/en/health_en/3053999 Thu, 13 May 2021 13:00:00 +0700 health_en https://www.thaipr.net/en/health_en/3053999 Novo Nordisk today announced new results from the STEP phase 3a clinical trial programme, demonstrating potential benefits beyond weight loss for people with obesity being treated with semaglutide 2.4 mg. The trial showed that treatment with once-weekly semaglutide 2.4 mg led to significant improvements in physical functioning, such as climbing stairs and tying your shoes, […]

The post Semaglutide in people with obesity: boosts wellbeing and ability to perform daily physical activities appeared first on ThaiPR.NET.

]]> <![CDATA[Saxenda® recommended for approval by European Medicines Agency committee for the treatment of obesity in adolescents aged 12–17 years]]> https://www.thaipr.net/en/health_en/3042358 Mon, 29 Mar 2021 08:00:00 +0700 health_en https://www.thaipr.net/en/health_en/3042358 Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has recommended that the use of Saxenda® is expanded for the treatment of obesity in adolescents aged 12–17 years.1 Over the last 20 years, the global prevalence of obesity in children and adolescents has doubled from […]

The post Saxenda® recommended for approval by European Medicines Agency committee for the treatment of obesity in adolescents aged 12–17 years appeared first on ThaiPR.NET.

]]> <![CDATA[Adults with obesity treated with semaglutide 2.4 mg achieved and maintained a significant amount of weight loss in a 68-week trial]]> https://www.thaipr.net/en/health_en/3040908 Wed, 24 Mar 2021 08:25:32 +0700 health_en https://www.thaipr.net/en/health_en/3040908 Data presented at ENDO 2021 demonstrate clinically relevant weight loss, without weight regain, in people treated with semaglutide 2.4 mg vs placebo in combination with lifestyle intervention. New results from the STEP phase 3a clinical trial programme demonstrated weight loss with investigational treatment of once-weekly subcutaneous semaglutide 2.4 mg versus placebo. In the STEP 4 […]

The post Adults with obesity treated with semaglutide 2.4 mg achieved and maintained a significant amount of weight loss in a 68-week trial appeared first on ThaiPR.NET.

]]>